Chimeric antigen receptor T-cell therapy

From IDWiki
Revision as of 11:02, 1 February 2022 by Aidan (talk | contribs) (Created page with "== Background == * T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and r...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Background

  • T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and reinfused into the patient following a short course of chemotherapy
  • Used for relapsed or refractory B-cell acute lymphoblastic leukemia and high-grade B-cell lymphoma
Product Indications Target Antigen Survival
Tisagenlecleucel B-ALL and high-grade B-cell lymphoma CD19 76% 1-year OS in B-ALL; 8.3 month median OS in B-cell lymphoma
Axicabtagene ciloleucel high-grade B-cell lymphoma CD19 58% 18-month OS
Brexucabtagene autoleucel mantle cell lymphoma CD19 83% 1-year OS
Idecabtagene vicleucel multiple myeloma BCMA 11.8 month media PFS
Lisocabtagene maraleucal high-grade B-cell lymphoma CD19 18.8 month median OS
Retrieved from "https://idwiki.org/index.php?title=Chimeric_antigen_receptor_T-cell_therapy&oldid=8597"
Powered by MediaWiki
Powered by Semantic MediaWiki